tiprankstipranks
Trending News
More News >
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
Advertisement

Protagonist Therapeutics (PTGX) Stock Statistics & Valuation Metrics

Compare
689 Followers

Total Valuation

Protagonist Therapeutics has a market cap or net worth of $3.55B. The enterprise value is $2.95B.
Market Cap$3.55B
Enterprise Value$2.95B

Share Statistics

Protagonist Therapeutics has 62,211,320 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,211,320
Owned by Insiders1.64%
Owned by Institutions54.64%

Financial Efficiency

Protagonist Therapeutics’s return on equity (ROE) is 0.41 and return on invested capital (ROIC) is 35.69%.
Return on Equity (ROE)0.41
Return on Assets (ROA)0.37
Return on Invested Capital (ROIC)35.69%
Return on Capital Employed (ROCE)0.36
Revenue Per Employee3.50M
Profits Per Employee2.22M
Employee Count124
Asset Turnover0.58
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Protagonist Therapeutics is 80.0. Protagonist Therapeutics’s PEG ratio is ―.
PE Ratio80.0
PS Ratio
PB Ratio
Price to Fair Value3.52
Price to FCF
Price to Operating Cash Flow91.10
PEG Ratio

Income Statement

In the last 12 months, Protagonist Therapeutics had revenue of 434.43M and earned 275.19M in profits. Earnings per share was 4.47.
Revenue434.43M
Gross Profit431.47M
Operating Income252.84M
Pretax Income279.41M
Net Income275.19M
EBITDA252.84M
Earnings Per Share (EPS)4.47

Cash Flow

In the last 12 months, operating cash flow was 39.54M and capital expenditures -2.44M, giving a free cash flow of 37.10M billion.
Operating Cash Flow39.54M
Free Cash Flow37.10M
Free Cash Flow per Share0.60

Dividends & Yields

Protagonist Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.82
52-Week Price Change43.70%
50-Day Moving Average54.46
200-Day Moving Average46.34
Relative Strength Index (RSI)71.76
Average Volume (3m)619.64K

Important Dates

Protagonist Therapeutics upcoming earnings date is Nov 5, 2025, After Close (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date

Financial Position

Protagonist Therapeutics as a current ratio of 12.48, with Debt / Equity ratio of 1.69%
Current Ratio12.48
Quick Ratio12.48
Debt to Market Cap0.00
Net Debt to EBITDA-0.34
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Protagonist Therapeutics has paid 4.22M in taxes.
Income Tax4.22M
Effective Tax Rate0.02

Enterprise Valuation

Protagonist Therapeutics EV to EBITDA ratio is 9.06, with an EV/FCF ratio of 12.53.
EV to Sales5.27
EV to EBITDA9.06
EV to Free Cash Flow12.53
EV to Operating Cash Flow12.44

Balance Sheet

Protagonist Therapeutics has $570.47M in cash and marketable securities with $11.28M in debt, giving a net cash position of -$559.19M billion.
Cash & Marketable Securities$570.47M
Total Debt$11.28M
Net Cash-$559.19M
Net Cash Per Share-$8.99
Tangible Book Value Per Share$10.97

Margins

Gross margin is 99.70%, with operating margin of 58.20%, and net profit margin of 63.34%.
Gross Margin99.70%
Operating Margin58.20%
Pretax Margin64.32%
Net Profit Margin63.34%
EBITDA Margin58.20%
EBIT Margin58.20%

Analyst Forecast

The average price target for Protagonist Therapeutics is $69.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$69.20
Price Target Upside12.65% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast-34.45%
EPS Growth Forecast-69.75%

Scores

Smart Score8
AI Score59.5
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis